Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP). A phase II trial is planned to run for 5 years.

See also

  • CD20 antagonist

References


Zercepac Neues Trastuzumab Biosimilar APOTHEKE ADHOC

Veltassa 8,4 g Pulver zur, zum Herstell.e.Susp.z.Einn. 30 stk

Veltuzumab Effective for Refractory NonHodgkin’s Lymphoma CancerConnect

(PDF) Veltuzumab, an antiCD20 mAb for the treatment of nonHodgkin's

PharmaWiki Vedolizumab